Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Speaker Mike Johnson negotiated a number of last minute changes to the megabill to get it across the finish line, including ...

ReproNovo has licensed rights to two drugs from Mereo BioPharma and ObsEva that it thinks could address fertility issues in ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...

CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead ...

Agency drug reviewers had questioned patient risk criteria and the efficacy endpoint used in a key trial supporting J&J's ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...